Participated · Series B · Oct 2022

FEMSelect develops EnPlace®, a minimally invasive, meshless system for pelvic floor ligament fixation cleared by the FDA to manage symptomatic uterine prolapse. The technology enables a procedure in under 30 minutes, and clinical studies report women can return to normal activities within a few days. FEMSelect has partnered with LiNA Medical USA and has spent the past year educating physicians on the technology. The company obtained a CMS procedure code earlier this year, enabling healthcare facilities to receive reimbursement for the procedure. EnPlace is currently available in more than 25 US states. FEMSelect plans to use the Series B proceeds to support growth and market penetration of EnPlace, primarily in the US; the company is led by Co-CEOs Debbie Garner and Renee Selman. POP Medical Solutions Ltd. develops NeuGuide, a minimally-invasive, meshless and dissectionless surgical system to treat pelvic organ prolapse (POP). NeuGuide combines a Nitinol-based anchor, surgical sutures and an innovative attachment method and has received FDA clearance. The device was tested in a 15-patient trial in Israel and is currently being used by US physicians in a post-marketing study. POP plans to use new funding to complete the post-marketing study, obtain European CE Mark certification, transfer the product to mass production, and build a US commercial organization for an early 2019 launch. CEO Deborah Garner leads the company and MABA founder Bernie Rudnick will join POP's board as part of the financing.

Participated · Convertible Note · Jun 2022

Trusty.care is a New York-based insurtech that provides an AI-driven 360 sales enablement solution for the individual health insurance and Medicare distribution market. Its products are used by insurance sales professionals to streamline quoting, enrollment, commissions, contracting, and licensing workflows. For carriers and FMOs the platform aims to improve retention, reduce spend on manual processes, and improve NPS. Trusty.care’s distribution model reaches consumers through partnerships, brokers, and carriers; contracted brokers grew from 1,000 to 50,000 in the last 18 months and the company works with 300+ health plan customers. The company plans to use new capital to grow the team, forge partnerships, ramp marketing, launch a Medicare Advantage retention product, and expand digital enrollment to 200+ health plans. The round brings Trusty.care’s total funding to $13M. Trusty.care operates a dual-facing digital platform that helps health insurance brokers and financial advisors identify financial risks older clients may face from healthcare costs. The platform matches customers with insurance products, public benefits, and cost-saving tools and includes both a consumer-facing marketplace and a broker-facing SaaS. The company sells its product on a per-broker SaaS basis and takes a share of transaction fees on the marketplace. Trusty.care's founders were inspired by hands-on eldercare experience and personal family healthcare events; CEO and cofounder Joseph Schneier discussed this background. The team is building data science behind a COVID-19 application that state governments are using to manage older adult residents, and they are using that data to inform their insurance business. The company has moved from pre-revenue to converting customers to paying and plans to reach 15,000 brokers and at least $100K MRR in the next six months. To date Trusty.care has raised $4.3M in total capital across multiple rounds. Trusty.care is a New York-based healthcare technology startup that provides a senior-focused, data-driven platform for Medicare beneficiaries. The platform uses predictive analytics to help reduce healthcare costs for seniors. It soft-launched on Oct. 15, 2018, providing data on 100 Medicare-covered medications. The platform has been authorized by CMS for integration with beneficiary claims data via Blue Button 2.0. The company raised $800k in pre-seed funding and intends to use the proceeds to expand operations and its business reach. Trusty.care is led by CEO Joseph Schneier.

Participated · Seed · Jul 2021

DynamiCare Health offers an evidence-based digital platform to reinforce recovery from addiction through smartphone-delivered breath and saliva tests, GPS-verified treatment attendance check-ins, telehealth recovery coaching, and rewards deposited on a smart debit card that blocks cash withdrawals and spending at bars and liquor stores. The company says three published clinical trials validate its effectiveness, showing 2–3x improvements in quit rates across drugs, alcohol, and tobacco. Its digital care program is already being used by major health plans, health systems, and research universities. DynamiCare was founded in 2016 by Eric Gastfriend and David R. Gastfriend. The company raised an additional $1.5M in seed funding, bringing total equity funding to $5.6M, and has won over $3M in awards and grants, including three NIH grants. It plans to use the new funds to roll out its program across health plans, employers, government agencies, and the direct-to-consumer market. DynamiCare Health, founded in 2016 and based in Boston, offers an evidence-based digital platform to support addiction recovery. Its core product is a behavioral intervention app that automates Contingency Management by delivering random breath and saliva tests via phone, GPS-verified treatment attendance check-ins, and supportive telehealth recovery coaching. The platform issues rewards for healthy progress via deposits onto a smart debit card that blocks cash withdrawals and spending at bars and liquor stores. The company planned to roll the app directly to consumers later this spring and to advance its telehealth recovery coaching service. DynamiCare’s incentive-driven approach is grounded in research—Contingency Management has been shown effective in over 100 randomized controlled trials—and the technology was already being used at seven addiction treatment programs across the country. Founders are Eric Gastfriend, a Harvard MBA tech executive, and his father David R. Gastfriend, MD, an international expert in addiction psychiatry. The company raised seed funding to support these product rollouts and service expansion.

Participated · Series A · Jun 2021

Allotrope Medical develops StimSite™, an FDA-cleared smooth muscle stimulation device that leverages surgeons’ existing laparoscopic and robotic instruments to identify and locate the ureter during pelvic operations. The company is led by founder and CEO Albert Huang, MD, and is based in Houston, TX. StimSite™ is positioned as an intraoperative tool to reduce ureteral injury risk by improving ureter visualization. Allotrope Medical intends to use newly raised funds to accelerate its commercialization plans. The company closed a $4M Series A financing to support those efforts. No operating metrics were disclosed in the article. Allotrope Medical is a Houston-based medical device company developing an innovative surgical device intended to identify ureters and decrease the rate of injury during surgery. The company is led by Founder and CEO Albert Huang MD and is advancing the device through continued development funded by a recent financing. The round was led by Houston Health Ventures with syndication support from the Houston Angel Network; the amount raised was undisclosed. In conjunction with the financing, David Franklin, Managing Director of HHV, will join the Board of Directors alongside Donald Gonzales MD (Founder/CMO, Spirox Inc.) and Mira Sahney (former SVP and GM, Gynecology and ENT Divisions, Smith & Nephew). Allotrope said it will use the funds to continue device development and is targeting commercial availability in late 2018. No operating metrics or prior funding details were disclosed in the article.

Participated · Equity · Mar 2020

Kinnos's core product, Highlight, is a patented, hospital-grade color additive platform that temporarily colors disinfectant wipes and solutions to provide staff with an instantaneous visual cue to improve disinfection quality. Highlight is Star Registered by the Global Biorisk Advisory Council and recognized by the World Health Organization; a peer-reviewed study in the American Journal of Infection Prevention found it improved disinfection quality by as much as 70%. Highlight is already in use by hospitals, first responders, and transit agencies around the world and the company positions the product as a way to raise the standard of care for cleanliness and infection prevention. Kinnos was founded in 2015 during the Ebola outbreak and is headquartered in Brooklyn, NY. The company announced a $15 million financing to meet growing healthcare industry demand and to scale commercial deployment. It also named healthcare veteran Steve Fanning as CEO to lead rapid growth and commercialization. Kinnos is a New York–based startup that makes colorized disinfectant additives to ensure surfaces are covered. Its core products are Highlight powder, a patented additive dissolved into bulk bleach that colors solutions blue and fades after a few minutes, and Highlight wipes, which impregnate wipes at point of use. The company primarily targets hospitals and healthcare settings and has sold to humanitarian organizations deployed to Liberia, Guinea, Haiti, DR Congo and Uganda, with recent shipments to China amid the coronavirus outbreak. Kinnos is a five-person company founded six years ago and conducts third‑party testing to ensure its additive does not reduce disinfectant potency. The additive lasts about five hours in a bucket of bleach and fades on surfaces in about three minutes. After establishing a foothold in hospitals, the company is considering a consumer offering. Kinnos developed Highlight, a patent-pending additive for disinfectants designed to improve visibility, coverage, and end-user compliance. The product was created in response to the Ebola crisis in West Africa and has been field-tested in Liberia, Guinea, and Haiti. Highlight is used by the Fire Department of New York and Kinnos was a grantee of the USAID Fighting Ebola Grand Challenge. The company has received recognition including the Lemelson-MIT Student Prize, Collegiate Inventors Competition, and Columbia Venture Competition, and has been featured in the Wall Street Journal, Scientific American, and Forbes 30 Under 30 in Healthcare. Kinnos is led by CEO Jason Kang. Financially, Kinnos recently closed a $1M seed round led by Georgica Advisors with participation from New York Angels, VentureWell, and other strategic angel investors.